The Evolving Role of Cytodeductive Nephrectomy | Urology Grand Rounds (RECORDING)

Thursday, April 18, 2024, 12:00 AM - Saturday, April 17, 2027, 11:59 PM, On Demand

In this recorded Urology Grand Rounds presentation, Division Chief of Urologic Oncology, Associate Surgeon at Brigham and Women’s Hospital and Dana-Farber Brigham Cancer Center, and Assistant Professor of Surgery at Harvard Medical School, Dr. Steven L. Chang discusses the management of metastatic renal cell carcinoma, focusing on the role of cytoreductive nephrectomy. Dr. Chang begins with the historical development of treatment approaches, from the cytokine era with interleukin-2 and interferon alpha, to the targeted therapy era with agents like sunitinib, and the current era of immunotherapy and combination therapies. In his lecture, Dr. Chang reviews the CARMENA trial, a randomized controlled study which showed that sunitinib alone was non-inferior to cytoreductive nephrectomy plus sunitinib, challenging the previous standard of care. Dr. Chang then discusses four clinical scenarios where cytoreductive nephrectomy may still be beneficial. Dr. Changs’ presentation concludes by highlighting the importance of personalized, multidisciplinary care and the potential for future advancements such as vaccines and HIF2-alpha inhibitors.

 Release Date: April 18, 2024
  Expiration Date: April 17, 2027
  Estimated Time to Complete: 0.5 hours
  Registration Fee: FREE
 *Originally recorded 02/16/2024

AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Participation Credit (0.50 hours)

1. Consider cytoreductive nephrectomy for palliative purposes to relieve symptoms such as pain, hematuria, and paraneoplastic syndromes in patients with significant tumor burden.
2. Evaluate patients for consolidative cytoreductive nephrectomy after successful systemic therapy to eliminate residual disease.
3. Discuss the biopsy of larger tumors suspected of being metastatic to identify non-clear cell histologies.
4. Evaluate cytoreductive nephrectomy and metastasis-directed therapy for patients with oligometastatic disease.
5. Implement a multidisciplinary approach involving medical oncology for personalized treatment planning and decision-making.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Office.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

For References/Bibliography click here.

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

 

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity.

Faculty Member Information	Role in activity	Name of commercial interest/ Nature of relationship
Simon Conti, MD	Course Director and Reviewer	Nothing to Disclose
Steven L. Chang, MD, MS	Faculty	Nothing to Disclose